University of Health Sciences (UHS) has made all the necessary arrangements to launch the phase-III clinical trial of another Chinese vaccine for Coronavirus known as ‘ZF2001.’
According to details, the final stage clinical trial will start next week and will involve 1,000 volunteers aged 18 or above.
During a review meeting, Vice-Chancellor UHS, Prof. Dr. Javed Akram, said that the safety and efficacy of ZF2001 will be determined through a randomized, double-blind, placebo-controlled trial involving 1,000 volunteers of 18 years of age and above.
The study’s participants will be administered 3 doses of ZF2001 in three months after which the clinical trial will enter the follow-up stage.
All volunteers will be required to visit the trial site 7 times during the three months for which they will be paid Rs. 16,000 for food and travel expense.
ZF2001 has been developed by Anhui Zhifei Longcom, a Chinese biopharmaceutical company, in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.
Previously, UHS held the phase-III clinical trial of Ad5-nCoV, a Coronavirus vaccine developed by CanSino Biologics, a Chinese biotechnology company.
During the multination phase-III trial, the Cansino vaccine demonstrated 65% effectiveness at preventing symptomatic cases and 91% effectiveness at preventing severe infection.
As for the Pakistani subset, the vaccine offered 75% protection against symptomatic cases and 100% protection against severe infection.